- Conditions
- End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
- Interventions
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
- Diagnostic Test · Drug
- Lead sponsor
- Roderick Tan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension) Clear all
- Conditions
- Carotid Artery Disease
- Interventions
- Optison
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Echocardiography
- Interventions
- Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,039 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call
- Drug · Device · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Hypertension
- Interventions
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Elliott, Maryland
- Conditions
- Lymphedema Arm
- Interventions
- Lumason, Optison, Definity
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota